IXC invex therapeutics ltd

Ann: Invex Granted Key European Patent for Exenatide, page-9

  1. 336 Posts.
    lightbulb Created with Sketch. 147
    Great news.

    Added with the propriety formulation of Presendin and Orphan Drug Designation, the IP protection is formidable and befitting of a quality biotech.

    It appears the EU patent was granted only for ICP related to IIH whereas the US office was more flexible in allowing conditions related raised ICP including TBI, Hydrocephalus etc.

    Doesn’t seem to matter though. Once Invex takes Presendin to market for IIH, it’ll be bought out by Big Pharma before they expand to other large scale trials in other indications.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
9.0¢
Change
-0.001(1.10%)
Mkt cap ! $6.763M
Open High Low Value Volume
9.2¢ 9.4¢ 9.0¢ $831 9.1K

Buyers (Bids)

No. Vol. Price($)
2 75380 8.8¢
 

Sellers (Offers)

Price($) Vol. No.
9.7¢ 9000 1
View Market Depth
Last trade - 14.57pm 10/07/2025 (20 minute delay) ?
IXC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.